Novel small molecule compounds that modulate a new target for the treatment of asthma.
Despite its high prevalence, current therapeutic options for asthma are quite limited. Current therapies converge on modulation of the intracellular actin-myosin cross-bridging. The novel pathway identified by our investigators targets the interaction of the cell and the extracellular matrix to impair the ability of smooth muscle to transmit tension effectively. Therefore, this pathway has both the ability to independently mitigate airway contraction as well as the ability to adjunctively enhance the efficacy of current treatment regimens.
This novel invention provides the following advantages:
Investigators at the University of California, San Francisco have identified a novel target for the treatment of asthma and have developed novel small molecule inhibitors to this target. Delivery of low affinity inhibitors to this novel target has been shown to reduce the magnitude of airway narrowing in vivo in mice sensitized and challenged with ovalbumin, a widely used model of allergic asthma. In the same model, we found that mice with a specific deletion of this target in smooth muscle also have reduced airway narrowing. The ability of these novel compounds to inhibit cell adhesion mediated by this target was also demonstrated in vitro in colon carcinoma cell lines.
To develop and commercialize the small molecules as an effective treatment for asthma.
|United States Of America||Published Application||20190144386||05/16/2019||2016-026|
|European Patent Office||Published Application||2016-026|
|Patent Cooperation Treaty||Published Application||WO2019178248||09/19/2019||2018-073|